← Eichor
Condition: Oligometastatic Prostate Cancer Ompc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Oligometastatic Prostate Cancer Ompc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 3 · 147 location(s) · Novartis Pharmaceuticals · NCT05939414HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymp
NA · 1 location(s) · Institut Cancerologie de l'Ouest · NCT06978296Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT07090148
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.